33 results
Thumbnail

D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023

Thumbnail

D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters

Thumbnail

D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch

Thumbnail

D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Thumbnail

D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway

Thumbnail

D2.300 - Fixed Drug Eruption related to the use of NSAIDs

Thumbnail

D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test

Thumbnail

D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy

Thumbnail

D2.304 - Transepidermal Water Loss in Atopic Diseases

Thumbnail

D2.305 - Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol

Thumbnail

D2.306 - Sodium dodecyl sulfate impairs the skin epithelial barrier by inducing oxidative stress in human skin

Thumbnail

D2.307 - Diagnostic characterization of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): Case series from a tertiary care hospital and literature review

Thumbnail

D2.308 - Evaluation of ChatGPT Responses to Frequently Asked Questions by Parents of Children with Atopic Dermatitis

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience